Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02618889 · ClinicalTrials.gov registry record · Phase 4
OnabotulinumtoxinA in the Management of Psychogenic Dystonia
A Phase 4 study of Torticollis, Dystonia, sponsored by University of Cincinnati.
- Completed
- Registry status
- Phase 4
- Development phase
- 18
- Enrollment target
- 1
- Study location
NCT02618889: Completed Phase 4 study of Torticollis, Dystonia, sponsored by University of Cincinnati.
NCT02618889 is a Phase 4 study of Torticollis, Dystonia that has completed, run by University of Cincinnati. The registered enrollment target is 18 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02618889, a Phase 4 study of Torticollis, Dystonia, has completed, sponsored by University of Cincinnati.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 18 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this research study is to evaluate if patients with psychogenic dystonia treated with onabotulinumtoxinA (BOTOX) injections will demonstrate lower severity and disability at one month and at three months than those having received placebo injections
Primary Outcome
Primary outcome measures will be the combined severity, duration factor, and incapacitation scores (investigator-rated) of the Rating Scale for Psychogenic Movement Disorders (RSPMD, 0-12 per each limb and head \[maximum for all five regions: 60\]) (see Appendix 1).
Conditions Studied
Interventions
- BEHAVIORAL CBT
Study Locations (1)
Ohio
- Alberto Espay - Cincinnati
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2016-01-15 |
| Est. Completion | 2017-06-30 |
| Phase | Phase 4 |
What the finished NCT02618889 record still lists
NCT02618889 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 18 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (97% lower).
The record links to 1 condition, with Torticollis, Dystonia appearing as the primary indexed condition, and to 1 intervention - of which CBT is the first listed.
NCT02618889 reports a single indexed study location in Ohio.
Frequently Asked Questions
What is clinical trial NCT02618889 about?
NCT02618889 is a clinical study titled "OnabotulinumtoxinA in the Management of Psychogenic Dystonia". The purpose of this research study is to evaluate if patients with psychogenic dystonia treated with onabotulinumtoxinA (BOTOX) injections will demonstrate lower severity and disability at one month and at three months than those having received placebo injections
What is the current status of trial NCT02618889?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 18 participants. The study started on 2016-01-15. Estimated completion is 2017-06-30.
What conditions does trial NCT02618889 study?
This clinical trial studies the following conditions: Torticollis, Dystonia.
What interventions are being tested in trial NCT02618889?
The interventions under investigation include: CBT (BEHAVIORAL).
Who is sponsoring clinical trial NCT02618889?
This trial is sponsored by University of Cincinnati, which has 245 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02618889 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02618889's enrollment target sits among peer trials
18 1842nd of 2000 higher than 147 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01245179 · 18 participants · Phase 1
Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease
- NCT01999361 · 18 participants · NA
Prevention of de Novo Allosensitization in Islet Transplant Recipients Following Complete Graft Loss
- NCT02359825 · 18 participants · Phase 1
Nerve Repair Using Hydrophilic Polymers to Promote Immediate Fusion of Severed Axons and Swift Return of Function
- NCT02870244 · 18 participants · Phase 1
Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI